past
two
decad
new
infecti
threat
emerg
almost
yearli
outbreak
ebola
viru
diseas
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
zika
viru
diseas
interspers
epidem
avian
swine
influenza
develop
countri
focus
diseas
due
lassa
nipah
crimeancongo
haemorrhag
fever
virus
continu
unab
emerg
pathogen
sever
fever
thrombocytopenia
syndrom
viru
powassan
viru
remain
restrict
scope
ebola
detect
capit
citi
guinea
liberia
sierra
leon
potenti
global
pandem
expand
travel
affect
region
repatri
infect
healthcar
worker
becam
real
concern
ebola
recal
sever
acut
respiratori
syndrom
outbreak
hong
kong
toronto
rais
alarm
middl
east
respiratori
syndrom
outbreak
south
korea
zika
previous
consid
selflimit
newli
associ
syndrom
fetal
abnorm
ebola
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
zika
outbreak
highlight
substanti
vari
gap
vaccin
develop
first
vaccin
research
reactiv
even
ebola
despit
three
decad
vaccin
research
human
trial
limit
two
vaccin
candid
earli
second
vaccin
trial
occur
epidem
evolv
epidemiolog
third
fund
materialis
combat
outbreak
interest
financi
support
wane
case
preval
fell
immin
danger
reced
issu
highlight
urgent
need
coordin
consist
approach
vaccin
develop
emerg
emerg
pathogen
context
identifi
need
coordin
countermeasur
conven
consult
develop
socal
blueprint
infecti
diseas
epidem
potenti
although
organis
bill
melinda
gate
foundat
wellcom
trust
biomed
advanc
research
develop
author
provid
substanti
support
select
project
focu
area
mission
broader
vaccin
research
coalit
epidem
prepared
innov
cepi
conceiv
address
shortcom
issu
lancet
global
health
dimitrio
gougla
colleagu
present
cost
analysi
vaccin
develop
epidem
infecti
diseas
analysi
crucial
serv
guid
harmonis
finit
fund
monetari
need
achiev
cepi
goal
success
test
phase
least
one
vaccin
per
target
pathogen
although
part
cepi
mandat
eventu
object
success
vaccin
licensur
prioriti
pathogen
identifi
blueprint
candid
vaccin
preclin
clinic
develop
identifi
probabl
success
vaccin
advanc
success
stage
model
literatur
chanc
advanc
preclin
clinic
studi
composit
preval
success
phase
gougla
colleagu
actual
data
show
vaccin
advanc
phase
phase
although
consist
figur
slightli
lower
preval
drug
candid
licensur
estim
dimasi
colleagu
gougla
colleagu
stochast
model
base
actual
expenditur
provid
vaccin
develop
pipelin
vaccin
author
note
accuraci
selfreport
cost
figur
unknown
also
preval
report
provid
diseas
programm
cost
data
might
rudimentari
work
ongo
cost
develop
phase
includ
initi
discoveri
calcul
us
includ
risk
candid
nonadvanc
cost
per
success
candid
could
rang
million
consist
cost
estim
licensur
billion
per
success
candid
use
cost
estim
total
portfolio
cost
advanc
least
one
candid
vaccin
phase
target
pathogen
billion
point
stockpil
could
conceiv
occur
wwwthelancetcomlancetgh
vol
decemb
one
ask
whether
way
reduc
time
cost
phase
eventu
licensur
increas
potenti
success
cepi
fund
model
parallel
develop
multipl
candid
focu
platform
previou
known
success
key
limit
time
cost
anoth
area
consid
abil
efficaci
trial
might
feasibl
uncommon
geograph
dispers
diseas
sever
fever
thrombocytopenia
syndrom
viru
powassan
viru
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
although
potenti
solut
might
consid
groupspecif
approv
basi
success
vaccin
platform
relat
virus
final
cepi
model
provid
impetu
earlyphas
vaccin
develop
diseas
unknown
commerci
return
solut
encourag
develop
licensur
howev
still
need
geneon
life
scienc
inc
seoul
south
korea
depart
medicin
morristown
medic
center
morristown
nj
usa
jmaslow
geneonelsuscom
